<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:49:11 -0700</creation_date>
  <update_date>2013-05-27 11:04:13 -0600</update_date>
  <accession>HMDBP00161</accession>
  <secondary_accessions>
    <accession>5393</accession>
    <accession>HMDBP03760</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>MAO-B</synonym>
    <synonym>Monoamine oxidase type B</synonym>
  </synonyms>
  <gene_name>MAOB</gene_name>
  <general_function>Involved in oxidoreductase activity</general_function>
  <specific_function>Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
</specific_function>
  <pathways>
    <pathway>
      <name>Glycine, serine and threonine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00260</kegg_map_id>
    </pathway>
    <pathway>
      <name>Arginine and proline metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00330</kegg_map_id>
    </pathway>
    <pathway>
      <name>Histidine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00340</kegg_map_id>
    </pathway>
    <pathway>
      <name>Tyrosine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00350</kegg_map_id>
    </pathway>
    <pathway>
      <name>Phenylalanine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00360</kegg_map_id>
    </pathway>
    <pathway>
      <name>Tryptophan metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00380</kegg_map_id>
    </pathway>
    <pathway>
      <name>Drug metabolism - cytochrome P450</name>
      <smpdb_id/>
      <kegg_map_id>map00982</kegg_map_id>
    </pathway>
    <pathway>
      <name>Serotonergic synapse</name>
      <smpdb_id/>
      <kegg_map_id>map04726</kegg_map_id>
    </pathway>
    <pathway>
      <name>Dopaminergic synapse</name>
      <smpdb_id/>
      <kegg_map_id>map04728</kegg_map_id>
    </pathway>
    <pathway>
      <name>Cocaine addiction</name>
      <smpdb_id/>
      <kegg_map_id>map05030</kegg_map_id>
    </pathway>
    <pathway>
      <name>Amphetamine addiction</name>
      <smpdb_id/>
      <kegg_map_id>map05031</kegg_map_id>
    </pathway>
    <pathway>
      <name>Alcoholism</name>
      <smpdb_id/>
      <kegg_map_id>map05034</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB01248</accession>
      <name>FAD</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00022</accession>
      <name>3-Methoxytyramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01925</accession>
      <name>Ibuprofen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05038</accession>
      <name>Citalopram</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01510</accession>
      <name>Bupropion</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01848</accession>
      <name>Imipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12226</accession>
      <name>Entacapone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00051</accession>
      <name>Ammonia</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00068</accession>
      <name>Epinephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00073</accession>
      <name>Dopamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00087</accession>
      <name>Dimethylamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00164</accession>
      <name>Methylamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00216</accession>
      <name>Norepinephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00259</accession>
      <name>Serotonin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00303</accession>
      <name>Tryptamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00306</accession>
      <name>Tyramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00819</accession>
      <name>Normetanephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00898</accession>
      <name>1-Methylhistamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01167</accession>
      <name>Pyruvaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01190</accession>
      <name>Indoleacetaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01377</accession>
      <name>Oxygen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02017</accession>
      <name>1-Phenylethylamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02064</accession>
      <name>N-Acetylputrescine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02134</accession>
      <name>Aminoacetone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03125</accession>
      <name>Hydrogen peroxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03791</accession>
      <name>3,4-Dihydroxyphenylacetaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04061</accession>
      <name>3-Methoxy-4-hydroxyphenylglycolaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04063</accession>
      <name>Metanephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04073</accession>
      <name>5-Hydroxyindoleacetaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04076</accession>
      <name>5-Hydroxykynurenamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04077</accession>
      <name>4,6-Dihydroxyquinoline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04181</accession>
      <name>Methylimidazole acetaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04226</accession>
      <name>N4-Acetylaminobutanal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05175</accession>
      <name>Homovanillin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06236</accession>
      <name>Phenylacetaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06242</accession>
      <name>3,4-Dihydroxymandelaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01934</accession>
      <name>L(-)-Nicotine pestanal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14337</accession>
      <name>Phentermine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14739</accession>
      <name>Linezolid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14752</accession>
      <name>Furazolidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14890</accession>
      <name>Tranylcypromine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14918</accession>
      <name>Phenelzine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15045</accession>
      <name>Zonisamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15051</accession>
      <name>Amantadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15171</accession>
      <name>Selegiline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15302</accession>
      <name>Moclobemide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15377</accession>
      <name>Isocarboxazid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15454</accession>
      <name>Rasagiline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15517</accession>
      <name>Methamphetamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15563</accession>
      <name>Pargyline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15694</accession>
      <name>Nandrolone decanoate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03767</accession>
      <name>4-Hydroxyphenylacetaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12275</accession>
      <name>Phenylethylamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB60281</accession>
      <name>3-Hydroxykynurenamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB60289</accession>
      <name>Quinoline-4,8-diol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB60462</accession>
      <name>Citalopram aldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14021</accession>
      <name>N-Desmethylcitalopram</name>
    </metabolite>
    <metabolite>
      <accession>HMDB60472</accession>
      <name>Didemethylcitalopram</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>oxidation reduction</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>integral to membrane</description>
      <go_id>GO:0016021</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>mitochondrial inner membrane</description>
      <go_id>GO:0005743</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>mitochondrial outer membrane</description>
      <go_id>GO:0005741</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>electron carrier activity</description>
      <go_id>GO:0009055</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>flavin adenine dinucleotide binding</description>
      <go_id>GO:0050660</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>primary amine oxidase activity</description>
      <go_id>GO:0008131</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of serotonin secretion</description>
      <go_id>GO:0014063</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of dopamine metabolic process</description>
      <go_id>GO:0045964</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to aluminum ion</description>
      <go_id>GO:0010044</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to corticosterone stimulus</description>
      <go_id>GO:0051412</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to drug</description>
      <go_id>GO:0042493</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to ethanol</description>
      <go_id>GO:0045471</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to lipopolysaccharide</description>
      <go_id>GO:0032496</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to selenium ion</description>
      <go_id>GO:0010269</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to toxin</description>
      <go_id>GO:0009636</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>small molecule metabolic process</description>
      <go_id>GO:0044281</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>xenobiotic metabolic process</description>
      <go_id>GO:0006805</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Mitochondrion outer membrane</subcellular_location>
    <subcellular_location>Single-pass type IV membrane protein</subcellular_location>
    <subcellular_location>Cytoplasmic side</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>X</chromosome_location>
    <locus>Xp11.23</locus>
    <gene_sequence>&gt;1560 bp
ATGAGCAACAAATGCGACGTGGTCGTGGTGGGGGGCGGCATCTCAGGTATGGCAGCAGCC
AAACTTCTGCATGACTCTGGACTGAATGTGGTTGTTCTGGAAGCCCGGGACCGTGTGGGA
GGCAGGACTTACACTCTTAGGAACCAAAAGGTTAAATATGTGGACCTTGGAGGATCCTAT
GTTGGACCAACCCAGAATCGTATCTTGAGATTAGCCAAGGAGCTAGGATTGGAGACCTAC
AAAGTGAATGAGGTTGAGCGTCTGATCCACCATGTAAAGGGCAAATCATACCCCTTCAGG
GGGCCATTCCCACCTGTATGGAATCCAATTACCTACTTAGATCATAACAACTTTTGGAGG
ACAATGGATGACATGGGGCGAGAGATTCCGAGTGATGCCCCATGGAAGGCTCCCCTTGCA
GAAGAGTGGGACAACATGACAATGAAGGAGCTACTGGACAAGCTCTGCTGGACTGAATCT
GCAAAGCAGCTTGCCACTCTCTTTGTGAACCTGTGTGTCACTGCAGAGACCCATGAGGTC
TCTGCTCTCTGGTTCCTGTGGTATGTGAAGCAGTGTGGAGGCACAACAAGAATCATCTCG
ACAACAAATGGAGGACAGGAGAGGAAATTTGTGGGCGGATCTGGTCAAGTGAGTGAGCGG
ATAATGGACCTCCTTGGAGACCGAGTGAAGCTGGAGAGGCCTGTGATCTACATTGACCAG
ACAAGAGAAAATGTCCTTGTGGAGACCCTAAACCATGAGATGTATGAGGCTAAATATGTG
ATTAGTGCTATTCCTCCTACTCTGGGCATGAAGATTCACTTCAATCCCCCTCTGCCAATG
ATGAGAAACCAGATGATCACTCGTGTGCCTTTGGGTTCAGTCATCAAGTGTATAGTTTAT
TATAAAGAGCCTTTCTGGAGGAAAAAGGATTACTGTGGAACCATGATTATTGATGGAGAA
GAAGCTCCAGTTGCCTACACGTTGGATGATACCAAACCTGAAGGCAACTATGCTGCCATA
ATGGGATTTATCCTGGCCCACAAAGCCAGAAAACTGGCACGTCTTACCAAAGAGGAAAGG
TTGAAGAAACTTTGTGAACTCTATGCCAAGGTTCTGGGTTCCCTAGAAGCTCTGGAGCCA
GTGCATTATGAAGAAAAGAACTGGTGTGAGGAGCAGTACTCTGGGGGCTGCTACACAACT
TATTTCCCCCCTGGGATCCTGACTCAATATGGAAGGGTTCTACGCCAGCCAGTGGACAGG
ATTTACTTTGCAGGCACCGAGACTGCCACACACTGGAGCGGCTACATGGAGGGGGCTGTA
GAGGCCGGGGAGAGAGCAGCCCGAGAGATCCTGCATGCCATGGGGAAGATTCCAGAGGAT
GAAATCTGGCAGTCAGAACCAGAGTCTGTGGATGTCCCTGCACAGCCCATCACCACCACC
TTTTTGGAGAGACATTTGCCCTCCGTGCCAGGCCTGCTCAGGCTGATTGGATTGACCACC
ATCTTTTCAGCAACGGCTCTTGGCTTCCTGGCCCACAAAAGGGGGCTACTTGTGAGAGTC
</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>520</residue_number>
    <molecular_weight>58762.475</molecular_weight>
    <theoretical_pi>7.5</theoretical_pi>
    <pfams>
      <pfam>
        <name>Amino_oxidase</name>
        <pfam_id>PF01593</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Amine oxidase [flavin-containing] B
MSNKCDVVVVGGGISGMAAAKLLHDSGLNVVVLEARDRVGGRTYTLRNQKVKYVDLGGSY
VGPTQNRILRLAKELGLETYKVNEVERLIHHVKGKSYPFRGPFPPVWNPITYLDHNNFWR
TMDDMGREIPSDAPWKAPLAEEWDNMTMKELLDKLCWTESAKQLATLFVNLCVTAETHEV
SALWFLWYVKQCGGTTRIISTTNGGQERKFVGGSGQVSERIMDLLGDRVKLERPVIYIDQ
TRENVLVETLNHEMYEAKYVISAIPPTLGMKIHFNPPLPMMRNQMITRVPLGSVIKCIVY
YKEPFWRKKDYCGTMIIDGEEAPVAYTLDDTKPEGNYAAIMGFILAHKARKLARLTKEER
LKKLCELYAKVLGSLEALEPVHYEEKNWCEEQYSGGCYTTYFPPGILTQYGRVLRQPVDR
IYFAGTETATHWSGYMEGAVEAGERAAREILHAMGKIPEDEIWQSEPESVDVPAQPITTT
FLERHLPSVPGLLRLIGLTTIFSATALGFLAHKRGLLVRV</protein_sequence>
  </protein_properties>
  <genbank_protein_id/>
  <uniprot_id>P27338</uniprot_id>
  <uniprot_name>AOFB_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1GOS</pdb_id>
    <pdb_id>1H8R</pdb_id>
    <pdb_id>1OJ9</pdb_id>
    <pdb_id>1OJA</pdb_id>
    <pdb_id>1OJC</pdb_id>
    <pdb_id>1OJD</pdb_id>
    <pdb_id>1S2Q</pdb_id>
    <pdb_id>1S2Y</pdb_id>
    <pdb_id>1S3B</pdb_id>
    <pdb_id>1S3E</pdb_id>
    <pdb_id>2BK3</pdb_id>
    <pdb_id>2BK4</pdb_id>
    <pdb_id>2BK5</pdb_id>
    <pdb_id>2BYB</pdb_id>
    <pdb_id>2C64</pdb_id>
    <pdb_id>2C65</pdb_id>
    <pdb_id>2C66</pdb_id>
    <pdb_id>2C67</pdb_id>
    <pdb_id>2C70</pdb_id>
    <pdb_id>2C72</pdb_id>
    <pdb_id>2C73</pdb_id>
    <pdb_id>2C75</pdb_id>
    <pdb_id>2C76</pdb_id>
    <pdb_id>2V5Z</pdb_id>
    <pdb_id>2V60</pdb_id>
    <pdb_id>2V61</pdb_id>
    <pdb_id>2VRL</pdb_id>
    <pdb_id>2VRM</pdb_id>
    <pdb_id>2VZ2</pdb_id>
    <pdb_id>2XCG</pdb_id>
    <pdb_id>2XFN</pdb_id>
    <pdb_id>2XFO</pdb_id>
    <pdb_id>2XFP</pdb_id>
    <pdb_id>2XFQ</pdb_id>
    <pdb_id>2XFU</pdb_id>
    <pdb_id>3PO7</pdb_id>
    <pdb_id>3ZYX</pdb_id>
    <pdb_id>4A79</pdb_id>
    <pdb_id>4A7A</pdb_id>
  </pdb_ids>
  <genbank_gene_id>S62734</genbank_gene_id>
  <genecard_id>MAOB</genecard_id>
  <geneatlas_id>MAOB</geneatlas_id>
  <hgnc_id>HGNC:6834</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Grimsby J, Chen K, Wang LJ, Lan NC, Shih JC: Human monoamine oxidase A and B genes exhibit identical exon-intron organization. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3637-41.</reference_text>
      <pubmed_id>2023912</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bach AW, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC: cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4934-8.</reference_text>
      <pubmed_id>3387449</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chen K, Wu HF, Shih JC: The deduced amino acid sequences of human platelet and frontal cortex monoamine oxidase B are identical. J Neurochem. 1993 Jul;61(1):187-90.</reference_text>
      <pubmed_id>8515265</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ross MT, Grafham DV, Coffey AJ, Scherer S, McLay K, Muzny D, Platzer M, Howell GR, Burrows C, Bird CP, Frankish A, Lovell FL, Howe KL, Ashurst JL, Fulton RS, Sudbrak R, Wen G, Jones MC, Hurles ME, Andrews TD, Scott CE, Searle S, Ramser J, Whittaker A, Deadman R, Carter NP, Hunt SE, Chen R, Cree A, Gunaratne P, Havlak P, Hodgson A, Metzker ML, Richards S, Scott G, Steffen D, Sodergren E, Wheeler DA, Worley KC, Ainscough R, Ambrose KD, Ansari-Lari MA, Aradhya S, Ashwell RI, Babbage AK, Bagguley CL, Ballabio A, Banerjee R, Barker GE, Barlow KF, Barrett IP, Bates KN, Beare DM, Beasley H, Beasley O, Beck A, Bethel G, Blechschmidt K, Brady N, Bray-Allen S, Bridgeman AM, Brown AJ, Brown MJ, Bonnin D, Bruford EA, Buhay C, Burch P, Burford D, Burgess J, Burrill W, Burton J, Bye JM, Carder C, Carrel L, Chako J, Chapman JC, Chavez D, Chen E, Chen G, Chen Y, Chen Z, Chinault C, Ciccodicola A, Clark SY, Clarke G, Clee CM, Clegg S, Clerc-Blankenburg K, Clifford K, Cobley V, Cole CG, Conquer JS, Corby N, Connor RE, David R, Davies J, Davis C, Davis J, Delgado O, Deshazo D, Dhami P, Ding Y, Dinh H, Dodsworth S, Draper H, Dugan-Rocha S, Dunham A, Dunn M, Durbin KJ, Dutta I, Eades T, Ellwood M, Emery-Cohen A, Errington H, Evans KL, Faulkner L, Francis F, Frankland J, Fraser AE, Galgoczy P, Gilbert J, Gill R, Glockner G, Gregory SG, Gribble S, Griffiths C, Grocock R, Gu Y, Gwilliam R, Hamilton C, Hart EA, Hawes A, Heath PD, Heitmann K, Hennig S, Hernandez J, Hinzmann B, Ho S, Hoffs M, Howden PJ, Huckle EJ, Hume J, Hunt PJ, Hunt AR, Isherwood J, Jacob L, Johnson D, Jones S, de Jong PJ, Joseph SS, Keenan S, Kelly S, Kershaw JK, Khan Z, Kioschis P, Klages S, Knights AJ, Kosiura A, Kovar-Smith C, Laird GK, Langford C, Lawlor S, Leversha M, Lewis L, Liu W, Lloyd C, Lloyd DM, Loulseged H, Loveland JE, Lovell JD, Lozado R, Lu J, Lyne R, Ma J, Maheshwari M, Matthews LH, McDowall J, McLaren S, McMurray A, Meidl P, Meitinger T, Milne S, Miner G, Mistry SL, Morgan M, Morris S, Muller I, Mullikin JC, Nguyen N, Nordsiek G, Nyakatura G, O'Dell CN, Okwuonu G, Palmer S, Pandian R, Parker D, Parrish J, Pasternak S, Patel D, Pearce AV, Pearson DM, Pelan SE, Perez L, Porter KM, Ramsey Y, Reichwald K, Rhodes S, Ridler KA, Schlessinger D, Schueler MG, Sehra HK, Shaw-Smith C, Shen H, Sheridan EM, Shownkeen R, Skuce CD, Smith ML, Sotheran EC, Steingruber HE, Steward CA, Storey R, Swann RM, Swarbreck D, Tabor PE, Taudien S, Taylor T, Teague B, Thomas K, Thorpe A, Timms K, Tracey A, Trevanion S, Tromans AC, d'Urso M, Verduzco D, Villasana D, Waldron L, Wall M, Wang Q, Warren J, Warry GL, Wei X, West A, Whitehead SL, Whiteley MN, Wilkinson JE, Willey DL, Williams G, Williams L, Williamson A, Williamson H, Wilming L, Woodmansey RL, Wray PW, Yen J, Zhang J, Zhou J, Zoghbi H, Zorilla S, Buck D, Reinhardt R, Poustka A, Rosenthal A, Lehrach H, Meindl A, Minx PJ, Hillier LW, Willard HF, Wilson RK, Waterston RH, Rice CM, Vaudin M, Coulson A, Nelson DL, Weinstock G, Sulston JE, Durbin R, Hubbard T, Gibbs RA, Beck S, Rogers J, Bentley DR: The DNA sequence of the human X chromosome.  Nature. 2005 Mar 17;434(7031):325-37.</reference_text>
      <pubmed_id>15772651</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhu QS, Grimsby J, Chen K, Shih JC: Promoter organization and activity of human monoamine oxidase (MAO) A and B genes. J Neurosci. 1992 Nov;12(11):4437-46.</reference_text>
      <pubmed_id>1432104</pubmed_id>
    </reference>
    <reference>
      <reference_text>Newton-Vinson P, Hubalek F, Edmondson DE: High-level expression of human liver monoamine oxidase B in Pichia pastoris. Protein Expr Purif. 2000 Nov;20(2):334-45.</reference_text>
      <pubmed_id>11049757</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cesura AM, Gottowik J, Lahm HW, Lang G, Imhof R, Malherbe P, Rothlisberger U, Da Prada M: Investigation on the structure of the active site of monoamine oxidase-B by affinity labeling with the selective inhibitor lazabemide and by site-directed mutagenesis. Eur J Biochem. 1996 Mar 15;236(3):996-1002.</reference_text>
      <pubmed_id>8665924</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wu HF, Chen K, Shih JC: Site-directed mutagenesis of monoamine oxidase A and B: role of cysteines.  Mol Pharmacol. 1993 Jun;43(6):888-93.</reference_text>
      <pubmed_id>8316221</pubmed_id>
    </reference>
    <reference>
      <reference_text>Binda C, Newton-Vinson P, Hubalek F, Edmondson DE, Mattevi A: Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol. 2002 Jan;9(1):22-6.</reference_text>
      <pubmed_id>11753429</pubmed_id>
    </reference>
    <reference>
      <reference_text>Binda C, Li M, Hubalek F, Restelli N, Edmondson DE, Mattevi A: Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9750-5. Epub 2003 Aug 11.</reference_text>
      <pubmed_id>12913124</pubmed_id>
    </reference>
    <reference>
      <reference_text>Binda C, Hubalek F, Li M, Herzig Y, Sterling J, Edmondson DE, Mattevi A: Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J Med Chem. 2004 Mar 25;47(7):1767-74.</reference_text>
      <pubmed_id>15027868</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hubalek F, Binda C, Khalil A, Li M, Mattevi A, Castagnoli N, Edmondson DE: Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J Biol Chem. 2005 Apr 22;280(16):15761-6. Epub 2005 Feb 14.</reference_text>
      <pubmed_id>15710600</pubmed_id>
    </reference>
    <reference>
      <reference_text>Binda C, Hubalek F, Li M, Herzig Y, Sterling J, Edmondson DE, Mattevi A: Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis. J Med Chem. 2005 Dec 29;48(26):8148-54.</reference_text>
      <pubmed_id>16366596</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Dopamine</name>
        <accession>HMDB00073</accession>
      </metabolite>
      <reference>
        <reference_text>Bortolato M, Chen K, Shih JC: Monoamine oxidase inactivation: from pathophysiology to therapeutics.  Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1527-33. Epub 2008 Jul 4.</reference_text>
        <pubmed_id>18652859</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dopamine</name>
        <accession>HMDB00073</accession>
      </metabolite>
      <reference>
        <reference_text>Kaludercic N, Carpi A, Menabo R, Di Lisa F, Paolocci N: Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta. 2011 Jul;1813(7):1323-32. Epub 2010 Sep 24.</reference_text>
        <pubmed_id>20869994</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L(-)-Nicotine pestanal</name>
        <accession>HMDB01934</accession>
      </metabolite>
      <reference>
        <reference_text>Lewis AJ, Truman P, Hosking MR, Miller JH: Monoamine oxidase inhibitory activity in tobacco smoke varies with tobacco type.  Tob Control. 2012 Jan;21(1):39-43. Epub 2011 Jun 2.</reference_text>
        <pubmed_id>21636610</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Rothman RB: Does phentermine inhibit monoamine oxidase?  Lancet. 1999 Apr 17;353(9161):1362-3.</reference_text>
        <pubmed_id>10218558</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Rothman RB: Is phentermine an inhibitor of monoamine oxidase? A critical appraisal.  Synapse. 1999 May;32(2):141-5.</reference_text>
        <pubmed_id>10231134</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21.</reference_text>
        <pubmed_id>10799660</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Kilpatrick IC, Traut M, Heal DJ: Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release. Int J Obes Relat Metab Disord. 2001 Oct;25(10):1454-8.</reference_text>
        <pubmed_id>11673765</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Nandigama RK, Newton-Vinson P, Edmondson DE: Phentermine inhibition of recombinant human liver monoamine oxidases A and B.  Biochem Pharmacol. 2002 Mar 1;63(5):865-9.</reference_text>
        <pubmed_id>11911838</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Linezolid</name>
        <accession>HMDB14739</accession>
      </metabolite>
      <reference>
        <reference_text>Stevens DL, Dotter B, Madaras-Kelly K: A review of linezolid: the first oxazolidinone antibiotic.  Expert Rev Anti Infect Ther. 2004 Feb;2(1):51-9.</reference_text>
        <pubmed_id>15482171</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Linezolid</name>
        <accession>HMDB14739</accession>
      </metabolite>
      <reference>
        <reference_text>Taylor JJ, Wilson JW, Estes LL: Linezolid and serotonergic drug interactions: a retrospective survey.  Clin Infect Dis. 2006 Jul 15;43(2):180-7. Epub 2006 Jun 9.</reference_text>
        <pubmed_id>16779744</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Furazolidone</name>
        <accession>HMDB14752</accession>
      </metabolite>
      <reference>
        <reference_text>Timperio AM, Kuiper HA, Zolla L: Identification of a furazolidone metabolite responsible for the inhibition of amino oxidases. Xenobiotica. 2003 Feb;33(2):153-67.</reference_text>
        <pubmed_id>12623758</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Furazolidone</name>
        <accession>HMDB14752</accession>
      </metabolite>
      <reference>
        <reference_text>Ali BH: Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun. 1999 Oct;23(6):343-60.</reference_text>
        <pubmed_id>10543364</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Furazolidone</name>
        <accession>HMDB14752</accession>
      </metabolite>
      <reference>
        <reference_text>Hoogenboom LA, Tomassini O, Oorsprong MB, Kuiper HA: Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone. Food Chem Toxicol. 1991 Mar;29(3):185-91.</reference_text>
        <pubmed_id>2032659</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly.  Drugs Aging. 1998 Nov;13(5):341-55.</reference_text>
        <pubmed_id>9829163</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Shioda K, Nisijima K, Yoshino T, Kato S: Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome.  Neurosci Lett. 2010 Oct 4;482(3):216-9. Epub 2010 Jul 23.</reference_text>
        <pubmed_id>20655983</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Gatch MB, Taylor CM, Flores E, Selvig M, Forster MJ: Effects of monoamine oxidase inhibitors on cocaine discrimination in rats.  Behav Pharmacol. 2006 Mar;17(2):151-9.</reference_text>
        <pubmed_id>16495723</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Lang W, Masucci JA, Caldwell GW, Hageman W, Hall J, Jones WJ, Rafferty BM: Liquid chromatographic and tandem mass spectrometric assay for evaluation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose of MAO inhibitors: application of biomarkers in drug discovery. Anal Biochem. 2004 Oct 1;333(1):79-87.</reference_text>
        <pubmed_id>15351283</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Shioda K, Nisijima K, Yoshino T, Kato S: Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):633-40.</reference_text>
        <pubmed_id>15276688</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76.</reference_text>
        <pubmed_id>15049511</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3.</reference_text>
        <pubmed_id>14574774</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Cohen C, Curet O, Perrault G, Sanger DJ: Reduction of oral ethanol self-administration in rats by monoamine oxidase inhibitors. Pharmacol Biochem Behav. 1999 Nov;64(3):535-9.</reference_text>
        <pubmed_id>10548268</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Wiest SA, Steinberg MI: 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine. Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):209-16.</reference_text>
        <pubmed_id>10494892</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Loscher W, Lehmann H, Teschendorf HJ, Traut M, Gross G: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999 Mar;288(3):984-92.</reference_text>
        <pubmed_id>10027835</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Todd KG, Baker GB: GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord. 1995 Dec 13;35(3):125-9.</reference_text>
        <pubmed_id>8749840</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Finberg JP, Youdim MB: Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology. 2002 Dec;43(7):1110-8.</reference_text>
        <pubmed_id>12504917</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Chiche F, Le Guillou M, Chetrite G, Lasnier F, Dugail I, Carpene C, Moldes M, Feve B: Antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes. Mol Pharmacol. 2009 May;75(5):1052-61. Epub 2009 Feb 6.</reference_text>
        <pubmed_id>19201819</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Chenu F, El Mansari M, Blier P: Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area. Int J Neuropsychopharmacol. 2009 May;12(4):475-85. Epub 2008 Aug 13.</reference_text>
        <pubmed_id>18700056</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Wooters TE, Bardo MT: The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats. Behav Pharmacol. 2007 Nov;18(7):601-8.</reference_text>
        <pubmed_id>17912044</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly.  Drugs Aging. 1998 Nov;13(5):341-55.</reference_text>
        <pubmed_id>9829163</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3.</reference_text>
        <pubmed_id>14574774</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Pickar D, Murphy DL, Cohen RM, Campbell IC, Lipper S: Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients. Arch Gen Psychiatry. 1982 May;39(5):535-40.</reference_text>
        <pubmed_id>7092487</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH: The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf. 2006 Jan;5(1):157-68.</reference_text>
        <pubmed_id>16370964</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31.</reference_text>
        <pubmed_id>17768678</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. Epub 2009 Dec 4.</reference_text>
        <pubmed_id>19948168</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Murata M: Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des. 2004;10(6):687-93.</reference_text>
        <pubmed_id>14965331</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Murata M, Horiuchi E, Kanazawa I: Zonisamide has beneficial effects on Parkinson's disease patients.  Neurosci Res. 2001 Dec;41(4):397-9.</reference_text>
        <pubmed_id>11755227</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, Fukushima Y: Effects of zonisamide on dopaminergic system.  Epilepsy Res. 1995 Nov;22(3):193-205.</reference_text>
        <pubmed_id>8991786</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Murata M: Zonisamide: a new drug for Parkinson's disease.  Drugs Today (Barc). 2010 Apr;46(4):251-8.</reference_text>
        <pubmed_id>20502722</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Okada M: [Effects of carbamazepine and zonisamide on dopaminergic system in rat striatum and hippocampus]. Nihon Shinkei Seishin Yakurigaku Zasshi. 1994 Oct;14(5):337-54.</reference_text>
        <pubmed_id>7856330</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders.  Mini Rev Med Chem. 2008 Sep;8(10):968-75.</reference_text>
        <pubmed_id>18782051</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amantadine</name>
        <accession>HMDB15051</accession>
      </metabolite>
      <reference>
        <reference_text>Wesemann W, Ekenna O: Effect of 1-aminoadamantanes on the MAO activity in brain, liver, and kidney of the rat. Arzneimittelforschung. 1982;32(10):1241-3.</reference_text>
        <pubmed_id>6891223</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Chrisp P, Mammen GJ, Sorkin EM: Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging. 1991 May;1(3):228-48.</reference_text>
        <pubmed_id>1794016</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Heinonen EH, Myllyla V: Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.  Drug Saf. 1998 Jul;19(1):11-22.</reference_text>
        <pubmed_id>9673855</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>[No authors listed]Selegiline: a second look. Six years later: too risky in Parkinson's disease.  Prescrire Int. 2002 Aug;11(60):108-11.</reference_text>
        <pubmed_id>12199263</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Macleod AD, Counsell CE, Ives N, Stowe R: Monoamine oxidase B inhibitors for early Parkinson's disease.  Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898.</reference_text>
        <pubmed_id>16034956</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Magyar K, Tothfalusi L: Pharmacokinetic aspects of deprenyl effects.  Pol J Pharmacol Pharm. 1984 Jul-Aug;36(4):373-84.</reference_text>
        <pubmed_id>6441926</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Heinonen EH, Anttila MI, Lammintausta RA: Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites.  Clin Pharmacol Ther. 1994 Dec;56(6 Pt 2):742-9.</reference_text>
        <pubmed_id>7995016</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309.</reference_text>
        <pubmed_id>11978145</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors.  CNS Spectr. 2006 May;11(5):363-75.</reference_text>
        <pubmed_id>16641841</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22.</reference_text>
        <pubmed_id>17715422</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder.  Neuropsychiatr Dis Treat. 2007;3(5):527-37.</reference_text>
        <pubmed_id>19300583</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5.</reference_text>
        <pubmed_id>17823646</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Moclobemide</name>
        <accession>HMDB15302</accession>
      </metabolite>
      <reference>
        <reference_text>Fisar Z, Hroudova J, Raboch J: Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.  Neuro Endocrinol Lett. 2010;31(5):645-56.</reference_text>
        <pubmed_id>21200377</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isocarboxazid</name>
        <accession>HMDB15377</accession>
      </metabolite>
      <reference>
        <reference_text>Mason ST: Chronic administration of type A monoamine oxidase inhibitors increases duration of thiopentone anaesthesia in the rat. Physiol Behav. 1985 Aug;35(2):201-3.</reference_text>
        <pubmed_id>4070383</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isocarboxazid</name>
        <accession>HMDB15377</accession>
      </metabolite>
      <reference>
        <reference_text>Kettler R, Da Prada M, Burkard WP: Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr Scand Suppl. 1990;360:101-2.</reference_text>
        <pubmed_id>2248058</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rasagiline</name>
        <accession>HMDB15454</accession>
      </metabolite>
      <reference>
        <reference_text>Naoi M, Maruyama W: Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Expert Rev Neurother. 2009 Aug;9(8):1233-50.</reference_text>
        <pubmed_id>19673610</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rasagiline</name>
        <accession>HMDB15454</accession>
      </metabolite>
      <reference>
        <reference_text>Uzun M, Alp R, Uzlu E, Alp S, Citil M, Topcu B, Erdogan HM: Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits. Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):95-8.</reference_text>
        <pubmed_id>19499843</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rasagiline</name>
        <accession>HMDB15454</accession>
      </metabolite>
      <reference>
        <reference_text>Youdim MB, Weinstock M: Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol. 2001 Dec;21(6):555-73.</reference_text>
        <pubmed_id>12043833</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rasagiline</name>
        <accession>HMDB15454</accession>
      </metabolite>
      <reference>
        <reference_text>Chau KY, Cooper JM, Schapira AH: Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. Neurochem Int. 2010 Nov;57(5):525-9. Epub 2010 Jul 17.</reference_text>
        <pubmed_id>20624440</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rasagiline</name>
        <accession>HMDB15454</accession>
      </metabolite>
      <reference>
        <reference_text>Weinreb O, Amit T, Bar-Am O, Youdim MB: Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol. 2010 Nov;92(3):330-44. Epub 2010 Jun 19.</reference_text>
        <pubmed_id>20600573</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rasagiline</name>
        <accession>HMDB15454</accession>
      </metabolite>
      <reference>
        <reference_text>Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T: Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 2005 Jan 1-15;79(1-2):172-9.</reference_text>
        <pubmed_id>15573406</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rasagiline</name>
        <accession>HMDB15454</accession>
      </metabolite>
      <reference>
        <reference_text>Leegwater-Kim J, Bortan E: The role of rasagiline in the treatment of Parkinson's disease.  Clin Interv Aging. 2010 May 25;5:149-56.</reference_text>
        <pubmed_id>20517484</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rasagiline</name>
        <accession>HMDB15454</accession>
      </metabolite>
      <reference>
        <reference_text>Chen JJ, Swope DM, Dashtipour K: Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007 Sep;29(9):1825-49.</reference_text>
        <pubmed_id>18035186</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rasagiline</name>
        <accession>HMDB15454</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review.  Prog Neurobiol. 2005 Apr;75(6):406-33.</reference_text>
        <pubmed_id>15955613</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21.</reference_text>
        <pubmed_id>10799660</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Chrisp P, Mammen GJ, Sorkin EM: Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging. 1991 May;1(3):228-48.</reference_text>
        <pubmed_id>1794016</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Heinonen EH, Myllyla V: Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.  Drug Saf. 1998 Jul;19(1):11-22.</reference_text>
        <pubmed_id>9673855</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>[No authors listed]Selegiline: a second look. Six years later: too risky in Parkinson's disease.  Prescrire Int. 2002 Aug;11(60):108-11.</reference_text>
        <pubmed_id>12199263</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Macleod AD, Counsell CE, Ives N, Stowe R: Monoamine oxidase B inhibitors for early Parkinson's disease.  Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898.</reference_text>
        <pubmed_id>16034956</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Magyar K, Tothfalusi L: Pharmacokinetic aspects of deprenyl effects.  Pol J Pharmacol Pharm. 1984 Jul-Aug;36(4):373-84.</reference_text>
        <pubmed_id>6441926</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Heinonen EH, Anttila MI, Lammintausta RA: Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites.  Clin Pharmacol Ther. 1994 Dec;56(6 Pt 2):742-9.</reference_text>
        <pubmed_id>7995016</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309.</reference_text>
        <pubmed_id>11978145</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors.  CNS Spectr. 2006 May;11(5):363-75.</reference_text>
        <pubmed_id>16641841</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22.</reference_text>
        <pubmed_id>17715422</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder.  Neuropsychiatr Dis Treat. 2007;3(5):527-37.</reference_text>
        <pubmed_id>19300583</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5.</reference_text>
        <pubmed_id>17823646</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Villeneuve C, Caudrillier A, Ordener C, Pizzinat N, Parini A, Mialet-Perez J: Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8. Epub 2009 Jun 19.</reference_text>
        <pubmed_id>19542488</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Murphy DL, Karoum F, Pickar D, Cohen RM, Lipper S, Mellow AM, Tariot PN, Sunderland T: Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). J Neural Transm Suppl. 1998;52:39-48.</reference_text>
        <pubmed_id>9564606</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Fuentes JA, Ordaz A, Neff NH: Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur J Pharmacol. 1979 Jul 15;57(1):21-7.</reference_text>
        <pubmed_id>477738</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nandrolone decanoate</name>
        <accession>HMDB15694</accession>
      </metabolite>
      <reference>
        <reference_text>Birgner C, Kindlundh-Hogberg AM, Oreland L, Alsio J, Lindblom J, Schioth HB, Bergstrom L: Reduced activity of monoamine oxidase in the rat brain following repeated nandrolone decanoate administration. Brain Res. 2008 Jul 11;1219:103-10. Epub 2008 May 17.</reference_text>
        <pubmed_id>18539264</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
